2012
DOI: 10.1590/s0034-72802012000100013
|View full text |Cite
|
Sign up to set email alerts
|

Tratamento da DMRI exsudativa: revisão das drogas antiangiogênicas

Abstract: RESUMODegeneração Macular Relacionada à Idade (DMRI) exsudativa é a principal causa de perda visual severa em indivíduos acima de 50 anos nos países desenvolvidos. O fator de crescimento endotelial (VEGF) é considerado um dos mais importantes reguladores da angiogênese e da permeabilidade vascular . Drogas com atividade antiVEGF tem se mostrado eficaz em preservar ou melhorar a acuidade visual (AV) ao inibir a permeabilidade vascular e o crescimento neovascular nos pacientes tratados. Este artigo de revisão de… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 72 publications
(81 reference statements)
0
1
0
Order By: Relevance
“…This finding corroborates several studies that classify Ranibizumab as the drug of choice for various widely prevalent pathologies such as exudative AMD through the Marina, Anchor and Pier studies, for example. According to Garcia et al [41], Rosenfeld et al [42] and Brown et al [43] this drug is considered the gold standard for treatment due to its greater ease in crossing the vitreoretinal interface as it has a molecular weight of less than 48 kDa.…”
Section: Discussionmentioning
confidence: 99%
“…This finding corroborates several studies that classify Ranibizumab as the drug of choice for various widely prevalent pathologies such as exudative AMD through the Marina, Anchor and Pier studies, for example. According to Garcia et al [41], Rosenfeld et al [42] and Brown et al [43] this drug is considered the gold standard for treatment due to its greater ease in crossing the vitreoretinal interface as it has a molecular weight of less than 48 kDa.…”
Section: Discussionmentioning
confidence: 99%